Royal Paworth Hospital
Cambridge, CB2 0AY, United Kingdom
Location status: Recruiting
Location contact
Dariusz Wozniak
CONTACT
NCT Number: NCT06844370
Non-invasive ventilation (NIV) is commonly offered to people with Motor Neurone Disease (MND) who have breathing difficulties. It improves their quality of life and can prolong life by 6 months or more. It is initially used at night and typically set up during a hospital admission. By the time that they develop respiratory failure and need to start NIV, however, most patients require wheelchairs or have other significant health problems. Repeated travel to hospitals is increasingly difficult with increasing disability. It is possible to start and monitor NIV treatment at home. This may be more convenient for selected patients, though starting NIV is quite complex; it is not known if home treatment is as safe and effective as hospital-based treatment.
To establish this, 60 patients with MND who have indications for NIV will be recruited. They will be randomly allocated to a home-based treatment (home NIV set up plus home visits supported by telemonitoring) or hospital-based care (inpatient NIV set up plus outpatient NIV monitoring) and followed up at 1, 4 and 7 months. Alongside measures of treatment effectiveness, assessment of patient and carer preferences, quality of life, and cost-effectiveness will be undertaken.
In the additional qualitative part on this study, interviews with patients who took part in the main study and their carers will be conducted to understand in more depth their perspective on what makes for a good or bad experience with NIV, how the environment (home vs hospital) influences their NIV experience and what personal factors determine NIV use. Findings from the interviews will inform the design of a truly patient-centred NIV service.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Cambridge, CB2 0AY, United Kingdom
Location status: Recruiting
Dariusz Wozniak
CONTACT
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Providing ventilation support through non-invasive means
Time frame: measured at 1,4,7 months following NIV initiation
Daytime PaCO2 measured by arterial puncture
Time frame: measured at 4 weeks since starting NIV
Semi-structured interview with patients and their carers
Time frame: 1 month
Percent of patients using NIV for >=4hrs/night
Time frame: 1 , 4 and 7 months
NIV adherence (machine usage in hours/24hours)
Time frame: Survival since NIV initiation
Survival (in months)
Time frame: Up to 7 months from initiation of NIV
Number of additional planned and emergency hospital admissions
Time frame: 1 , 4 and 7 months
Number of NIV setting changes required
Time frame: Up to 7 months from initiation of NIV
Absolute costs and costs in relation to quality-adjusted life-years (using EQ-5D)
Time frame: 1,4,7 months
time spent with oxygen saturation <90%(TST90)
Time frame: 1,4,7 months
Bicarbonate
Time frame: 1,4,7 ,months
Measurement of quality of life using EQ-5D-5L questionnaire
Time frame: 1,4, 7 months
Quality of life measured using Severe Respiratory Insufficiency (SRI) questionnaire
Time frame: 1,4,7 ,months
Sleep quality measured with Pittsburgh Sleep Quality Index (PSQI)
Time frame: 7 months
Satisfaction with NIV and healthcare interactions measured with a visual analogue scale
Contact information is provided by the study sponsor or research team.
Dariusz Wozniak
CONTACT
Victoria Stoneman
CONTACT
Papworth Hospital NHS Foundation Trust
Other Gov
Home Initiation and Monitoring of Non-invasive Ventilation (NIV) Versus Hospital-based Care in People with Motor Neurone Disease (MND) : a Randomised Control Trial (RCT) and Qualitative Study
Acronym: HoHoNIV
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06820008
Amyotrophic Lateral Sclerosis, Behavior
Dublin, Ireland
View Trial DetailsNCT05292690
Amyotrophic Lateral Sclerosis, Autoimmune Diseases
Canterbury, Kent, United Kingdom
View Trial DetailsNCT03444428
Amyotrophic Lateral Sclerosis, Central Nervous System Diseases
London, United Kingdom
View Trial DetailsNCT02464852
Amyotrophic Lateral Sclerosis, Central Nervous System Diseases
Sheffield, South Yorkshire, United Kingdom
View Trial Details